Riskpilot← Back to searchSign inGet full accessVironova Herpes AB
ABBankruptOrg 5590085295Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2021
SEK 0
EBITDA margin
—
-39% vs 2020
Equity ratio
48.7%
Financial strength
Net profit 2021
SEK -1M
-41% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | SEK -947K | -39% |
| Net profit | SEK -1M | -41% |
| Total assets | SEK 345K | -59% |
| Equity | SEK 168K | +118% |
| Employees | 0 | — |
Legal name
Vironova Herpes AB
Org number
5590085295
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 mars 2015
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Uppgift om firmateckning saknas Registrerad styrelse saknas.
Company purpose
Bolaget ska bedriva medicinsk forskning och utveckling kring utveckling av läkemedel mot herpesvirus samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −647 | −816 | −638 | −681 | −947 |
| Depreciation & amort. | −33 | −33 | −33 | −33 | −61 |
| EBIT | −680 | −849 | −671 | −714 | −1 008 |
| Net financials | — | — | — | — | — |
| Profit before tax | −680 | −849 | −671 | −714 | −1 008 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −680 | −849 | −671 | −714 | −1 008 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 666 | 669 | 771 | 841 | 345 |
| Equity | 211 | 262 | 91 | 77 | 168 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 455 | 407 | 679 | 764 | 177 |
| Total debt | 455 | 407 | 679 | 764 | 177 |
EBITDA margin
-94700000.0%
This company
15.8%
Market median
-599367189% vs market
20172021
Equity ratio
48.7%
This company
38.2%
Market median
+27% vs market
20172021
Return on equity
-600.0%
This company
18.4%
Market median
-3361% vs market
20172021
Net profit margin
-100800000.0%
This company
8.1%
Market median
-1244444544% vs market
20172021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172021
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JO Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 90% | 90% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
M Homman AB
Vironova Herpes AB Board members of Vironova Herpes AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Olof Tilander | Chief Auditor | 0 companies |
| Bo Johan Lund | Deputy Board Member | 0 companies |
| Mohamed Homman Loudiye | Board of Directors | 0 companies |